Sector News

Philips taps BioIntelliSense’s symptom-tracking sticker for COVID-19, other chronic diseases

July 13, 2020
Life sciences

Philips announced plans to integrate BioIntelliSense’s health-tracking sticker into its remote patient monitoring programs, designed to observe at-risk patients after they head home from the hospital.

BioIntelliSense debuted this past January, with an FDA-cleared multisensor patch capable of logging not just vital signs, but symptoms—including individual events such as sneezes, coughs and vomiting.

Philips plans to use the company’s BioSticker, with its 30-day battery life, to help monitor people with chronic conditions such as diabetes, cancer and heart failure, as well as to support its telehealth programs. This also includes keeping clinicians connected with COVID-19 patients who may not require hospitalization, while watching for signs of deterioration.

“With more patients interacting with their doctors from home and more hospitals developing strategies to virtually engage with their patients, remote patient monitoring is now, more than ever, an essential tool,” said Roy Jakobs, who was named chief business leader for Philips’ connected care offerings earlier this year.

By monitoring signs such as skin temperature, pulse, respiratory rate, overall activity level and the frequency of coughs, Philips hopes the system can trigger earlier interventions in people quarantined at home with the coronavirus.

“Multi-parameter sensors are the natural next phase for remote monitoring, especially at a time when more patients are engaging with their physicians from home,” said James Mault, founder and CEO of BioIntelliSense.

“Clinicians need medical-grade monitoring and algorithmic clinical insights for COVID-19 exposure, symptoms and management,” Mault said. “Accelerated by the COVID-19 crisis, the practice of medicine has been irreversibly enlightened as to the safety and efficacy of virtual care.”

Under the collaboration, the BioSticker will first be used by the U.S. service provider Healthcare Highways across seven monitoring programs, including aimed at COVID-19. The others will focus on heart failure, high blood pressure, diabetes, total joint replacement, cancer and asthma.

Meanwhile, Philips also announced a 10-year contract worth up to $100 million with the U.S. Department of Veterans Affairs, to expand its tele-ICU and connected critical care programs, as well as work in diagnostic imaging, sleep solutions and remote patient monitoring.

The VA manages 1,800 ICU beds nationwide, but—like much of the industry—has greatly expanded its telehealth work during the COVID-19 pandemic. From February to May, the VA’s number of video-to-home appointments exploded from about 10,000 up to 120,000 per week.

By: Conor Hale

Source: Fierce Biotech

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 23, 2021

Thermo Fisher Scientific acquires Novasep’s Henogen for $874.5m

Life sciences

Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash. Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.

January 23, 2021

Lilly and Merus partner to develop T-Cell re-directing antibody therapies

Life sciences

Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.

January 23, 2021

Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer

Life sciences

Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.

Send this to a friend